Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Difference in Chemotherapy for Lung Cancer between Asian and Caucasian].

Gan to kagaku ryoho. Cancer & chemotherapy - 1 Jan 2023

Kenmotsu Hirotsugu

Abstract excerpt

Currently, targeted therapies or immune checkpoint inhibitors(plus cytotoxic chemotherapy), have been used for patients with stage Ⅳ non-small cell lung cancer as first-line treatment, based on driver gene alterations. In Asia, EGFR mutation- positive non-small cell lung cancer patients are more frequently observed, and many clinical trials using EGFR tyrosine- kinase inhibitors have been conducted. It has been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Docetaxel

Share to ErbB Receptors

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 36759979

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Difference in Chemotherapy for Lung Cancer between Asian and Caucasian].PMID 36759979Read ↗

[Lung cancer: progress in diagnosis and treatments. Topics: III. Treatment; 3. Chemotherapy for patients with non-small cell lung cancer, 2) Driver mutation and molecular-targeted therapy in lung cancer].Semantic proximity Read ↗

[Potential Value of Neoadjuvant Immunochemotherapy in Patients with Driver Gene-positive Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Development of molecular targeted therapies in lung cancers].Semantic proximity Read ↗

[Research Progress of Immunotherapy for Non-small Cell Lung Cancer with Drive Gene Mutation].Semantic proximity Read ↗

Emerging paradigms in targeted treatments for Asian patients with NSCLC.Semantic proximity Read ↗

[Recent changes in the therapeutic strategy for NSCLC in association with new anti-cancer agents].Semantic proximity Read ↗

[Responses to targeted therapies: lung cancer].Semantic proximity Read ↗

[Treatment of advanced NSCLC with unknown EGFR gene status --TKI or chemotherapy?].Semantic proximity Read ↗

[Precision medical treatment of non-adenocarcinoma NSCLC patients with EGFR mutation].Semantic proximity Read ↗

[A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage ⅢA EGFR-mutant lung adenocarcinoma].Semantic proximity Read ↗

The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology.Semantic proximity Read ↗

Individualized treatment of NSCLC: from research to clinical practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.